Miller Barondess Files Lawsuit Against Nissan North America Over Alleged Scheme to Undermine Successful Automotive Dealer
28.3.2025 01:02:00 CET | Business Wire | Press release
Trophy Universal City Group, LLC and Trophy West Covina Motor Group, LLC (“Trophy Group”) have filed a lawsuit against Nissan North America, Inc., accusing the automaker of orchestrating a deliberate and nefarious scheme to suffocate vehicle inventory and squeeze out the Trophy Group. The case centers on two Los Angeles County Nissan dealerships—Universal City Nissan and West Covina Nissan—led by global automotive entrepreneur and Trophy Group founder and CEO, Nasser Watar, only to face what Trophy Group alleges is retaliatory sabotage by Nissan. Trophy Group is represented by Amnon Siegel and Bryan Redfern of Miller Barondess, LLP.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250327109484/en/
A Legacy of Success and Partnership
Since Trophy Group’s founding more than ten years ago, Nasser Watar, a veteran of the automotive industry, expanded Trophy Group to operate numerous successful dealerships in Southern California, including leading brands such as Mercedes-Benz and Kia. Its dealerships rank among the top-selling in the nation for their respective brands.
In addition to his U.S. operations, Watar has played a significant role in Nissan’s international distribution, particularly in the Middle East. From 2008 to 2019, he served as Vice Chairman, President and CEO of Nissan Gulf Company, a joint venture between Nissan Motor Co., Ltd. (“Nissan Japan”) and Al-Dahana Group. During Al-Dahana’s joint venture with Nissan Japan, Watar was CEO of Al-Dahana, as well as Nissan Gulf. Under Watar’s leadership, Nissan Gulf significantly expanded Nissan’s market presence, becoming the second-largest market leader in the Middle East and the most profitable Nissan subsidiary worldwide.
Nissan’s Initial Plea for Help
In 2017, recognizing Watar’s expertise, Nissan approached him to take over two struggling Los Angeles County dealerships—Universal City Nissan and West Covina Nissan. These once-successful dealerships had fallen into financial distress under their previous owner, Sage Automotive Group. Nissan sought Watar’s leadership to restore them to profitability, and Trophy Group acquired the dealerships. Initially, the transition was positive. With Nissan’s support, Watar and his team worked diligently to rebuild the dealerships’ reputation and performance.
Retaliation Following the Ghosn Scandal
In 2018, the arrest of former Nissan Japan CEO Carlos Ghosn sparked global controversy. As details emerged, Nissan Japan sought to sever ties with individuals and entities linked to the scandal—including Watar’s former business partner at Al-Dahana. Despite no allegations against Watar himself, Nissan unilaterally terminated its Gulf distribution partnership, prompting Al-Dahana to file suit. In 2021, Al-Dahana secured a $354 million judgment against Nissan Japan in Dubai.
In response, Nissan allegedly undertook a secret retaliatory campaign against Watar and Trophy Group’s U.S. dealerships, aiming to drive them out of business. Per the complaint, Nissan systematically under-allocated vehicles to Universal City Nissan and West Covina Nissan, depriving them of essential inventory while favoring nearby competitors.
The Impact of Nissan’s Unlawful Actions
New vehicle allocation is the lifeblood of any dealership, and Nissan’s alleged actions created a devastating cycle: reduced inventory led to lower sales, which in turn resulted in further reduced allocations. Despite Watar’s repeated pleas for fair treatment, Nissan allegedly refused to provide the necessary inventory, deliberately crippling the Trophy Group’s Nissan dealerships and eventually forcing them to close their doors.
Nissan’s alleged actions have resulted in millions in damages to Trophy Group and have also deprived consumers of competitive options in the Los Angeles market. Trophy Group is pursuing all available legal remedies against Nissan for its alleged targeted campaign of economic destruction.
“Nissan’s conduct represents an abuse of power and a blatant disregard for proper and fair business practices,” said Amnon Siegel. “We will not allow Nissan to unlawfully eliminate a trusted and dedicated dealer through manipulation and bad faith and look forward to the opportunity to present our case to a jury.”
The case is Trophy Universal City Group, LLC, et al. v. Nissan North America, Inc., et al., Los Angeles County Superior Court, Case No. [pending]
About Miller Barondess, LLP:
Miller Barondess, LLP is a Los Angeles-based law firm that specializes in litigation, including trial, arbitration, and appellate proceedings in California and nationwide. The firm represents both plaintiffs and defendants across a wide range of sectors, including automotive, consumer products, private equity, securities, financial services, intellectual property, patents, licensing and branding, technology and cybersecurity, real estate, healthcare, entertainment and music, sports, insurance, retail, environmental, and government. With a reputation for winning bet-the-company litigation, the firm is frequently engaged to resolve pivotal issues before trial, and other law firms bring in Miller Barondess when their clients need a trial or appellate team.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250327109484/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom